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EDITORIAL
Towards better management of chronic atrial fibrillation
Important lessons should be drawn from two recently
published randomised clinical trials comparing rhythm
control and rate control strategies directed at the manage-
ment of chronic atrial fibrillation in representative patient
populations. In the larger Atrial Fibrillation Follow-up
Investigation of Rhythm Management (AFFIRM) trial,1
4060 patients were followed up for an average of 3.5 years,
the rhythm control group did not fare better than those
assigned to rate control. Respective rates for death, the
composite end-point (death, disabling stroke, anoxic en-
cephalopathy, major bleed, or cardiac arrest), and numbers
hospitalised were 18% versus 15%, 22% versus 21%, and
68% versus 60%; the latter difference being statistically
significant (P<0.001). Similarly, in the European trial2 with
only 522 patients followed up for an average of 2.3 years,
the composite end-point (cardiovascular death, heart failure,
thromboembolism, bleeding, pacemaker implantation, or
severe drug adverse effect) ensued in 23% and 17% of the
patients assigned to the corresponding groups. Moreover,
in both trials most patients who had thromboembolic
complications, anticoagulation therapy had ceased or was
‘sub-therapeutic’. In summary, these trials provide compel-
ling evidence pointing to the clinical and financial burdens
imposed by current rhythm control interventions. Thus,
if symptoms are not an issue in the course of rate control,
the primary focus of management should be redirected to
better implementation of long-term anticoagulation, the only
strategy of proven benefit.
It is therefore opportune, that this issue of the Hong Kong
Medical Journal contains a report by Leung and Tam3
addressing this very point in a local context. The article de-
scribes findings from a retrospective audit of antithrombotic
therapy for patients with a primary or secondary diagnosis
of chronic atrial fibrillation, who were attending a non-
teaching regional hospital. In the hospital concerned, long-
term antithrombotic therapy (the prescribing of aspirin or
warfarin as well as any necessary international normalised
ratio [INR] monitoring) was undertaken by individual
physicians and not in a dedicated anticoagulation clinic.
The authors acknowledge the limitations of their audit (in-
sufficient patient numbers, methodological assumptions,
incomplete patient follow-up, and retrospective retrieval of
data from computerised records). Their results are never-
theless highly pertinent to practitioners in Hong Kong. Thus,
an ‘appropriate’ choice of antithrombotic therapy (in accord-
ance with American College of Chest Physicians Guidelines)
was made for 143 (69%) of the 207 patients whose records
were audited. Among the latter, 64 (34%), 93 (45%), and
50 (24%) patients, respectively, were receiving warfarin,
aspirin, or neither. Despite approximately 18% of the
patients only receiving aspirin although they qualified for
warfarin, and a further 13% receiving no antithrombotic
therapy although they were eligible, these figures appear at
least as encouraging as those reported by groups in North
America and Europe.4,5 At the same time, there was no
obvious excess in the rate of untoward haemorrhagic events,
which is contrary to the widely held opinion that Chinese
people are more prone to bleeding than other races. Leung
and Tam3 suggested that a higher rate of bleeding was not
encountered because the estimated mean/median INR in
their warfarin-treated patients was approximately 2.0,
whereas western guidelines advocate target values ranging
between 2.0 and 3.0. It follows that, just as for recurrent
venous thromboembolism,6 there is a need to confirm the
effectiveness of long-term low-intensity warfarin therapy
for chronic atrial fibrillation, particularly among Chinese
patients.
The findings of the audit by Leung and Tam3 have
obvious implications for the local community. Namely, that
even outside the context of teaching hospitals, it is feasible
to offer appropriate antithrombotic therapy to the vast
majority of eligible Hong Kong patients with chronic atrial
fibrillation.
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